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Abstract
Background: Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels comprised of five similar
subunits that influence signal transduction and cell turnover. a5 is a structural subunit detected in many non-
neuronal tissues; however, its function during pulmonary development is unknown.
Results: a5 was assessed by immunohistochemistry and RT-PCR in mouse lungs from embryonic day (E)13.5 to
post-natal day (PN)20. From E13.5 to E18.5, a5 expression was primarily observed in primitive airway epithelial cells
while mesenchymal expression was faint and sporadic. a5 expression was detected throughout the proximal lung
at PN1 and extensively expressed in the peripheral lung at PN4, an early stage of murine alveologenesis. An
interesting shift occurred wherein a5 expression was almost undetectable in the proximal lung from PN4-PN10, but
significant localization was again observed at PN20. Transcriptional control of a5 was determined by assessing the
activity of reporters containing 2.0-kb and 850-bp of the mouse a5 promoter. Because perinatal expression of a5
was abundant in bronchiolar and alveolar epithelium, we assessed transcriptional control of a5 in Beas2B cells, a
human bronchiolar epithelial cell line, and A-549 cells, an alveolar type II cell-like human epithelial cell line. Thyroid
Transcription Factor-1 (TTF-1), a key transcription regulator of pulmonary morphogenesis, significantly increased a5
transcription by acting on both the 2.0-kb and 850-bp a5 promoters. Site-directed mutagenesis revealed that TTF-1
activated a5 transcription by binding specific TTF-1 response elements. Exogenous TTF-1 also significantly induced
a5 transcription.
Conclusions: These data demonstrate that a5 is specifically controlled in a temporal and spatial manner during
pulmonary morphogenesis. Ongoing research may demonstrate that precise regulation of a5 is important during
normal organogenesis and misexpression correlates with tobacco related lung disease.
Background
Mechanisms that control pulmonary development
involve highly coordinated processes that require precise
reciprocal interactions between endodermally derived
respiratory epithelium and the surrounding splanchnic
mesenchyme. These interactions are predominantly
mediated by cell surface receptors and specific ligands
elaborated by communicating cells of both germinal ori-
gins. Initial primordial lung buds undergo branching to
form the main bronchi and extensive subsequent
branching events lead to the formation of the intrapul-
monary conducting and peripheral lung airways. Distinct
populations of differentiated respiratory epithelial cell
types then arise, producing a morphologically dynamic
arrangement of cells that in due course influence pul-
monary function and respiratory efficiency. The tem-
poral and spatial pattern of cell surface receptor
expression must therefore be specifically controlled
in order to orchestrate mechanisms of proliferation,
migration, and differentiation essential during lung
morphogenesis.
Thyroid transcription factor (TTF)-1 is a member of
the homeodomain-containing Nkx2 family of transcrip-
tion factors. TTF-1 is expressed in the lung, thyroid,
ventral forebrain, and the pituitary [1-3]. While TTF-1
mRNA is initially detected in the mouse at E10 [4] its
pattern of expression principally localizes to the lung
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activates the expression of genes critical to lung devel-
opment and function such as surfactant proteins (SPs),
Clara cell secretory protein (CCSP), various growth fac-
tors, and molecules required for normal host defense
and vasculogenesis [4,5]. Inactivation of TTF-1 causes
tracheo-esophageal fistulae and impairment of pulmon-
ary branching, leading to severe lung hypoplasia [6]. In
concert with other transcription factors, TTF-1 binds
TTF-1 response elements (TREs) in promoters of target
genes in order to regulate gene expression and cell dif-
ferentiation during lung morphogenesis. While our pre-
liminary studies and the work of others reveal that a5 is
detected in cells known to express TTF-1 [7-9], no reg-
ulatory mechanism has been proposed linking the two
in the lung to date.
Neuronal and non-neuronal nicotinic acetylcholine
receptors (nAChRs) combine with glycine, GABAA,a n d
5HT3 receptors to form a family of ligand-gated ion
channels [10]. nAChRs are pentameric oligomers com-
posed of five related subunits arranged around a central
ion channel that allows flow of calcium or sodium fol-
lowing ligand binding. Subsequent to ligand interaction,
pathways associated with intracellular signal transduc-
tion, proliferation, and apoptosis are induced [11-13].
Several receptor subunits have been identified and are
classified as either agonist binding (a2, a3, a4, a6, a7, a9
and a10) or structural (a5, b2, b3 and b4) [14,15]. Work
performed previously by our laboratory demonstrated
that a7 nAChRs, homomeric receptors composed of five
a7 subunits, are temporally controlled in the lung dur-
ing development and are transcriptionally regulated by
TTF-1 [16].
In the current investigation, we report that a5 nAChR
subunits are expressed in subsets of pulmonary epithe-
lial cells during stages of lung morphogenesis and that
these receptor subunits are regulated by TTF-1. This
research adds additional insight into TTF-1 regulation
of subunits involved in nAChR assembly by joining a5
and a7 in conserved regulatory pathways. Furthermore,
because comparisons between the human a5 gene and
the a5 gene in several other species reveal remarkable
conservation, TTF-1 and its homologues may be com-
mon transcriptional regulators involved in controlling
the precision of a5 nAChR expression in the lung.
Methods
Mouse Models
a5 expression was assessed from E13.5 to PN20 in lungs
from wild type and TTF-1 null mice, each in a C57Bl/6
background. Dr. Jeffrey Whitsett at the Cincinnati Chil-
dren’s Hospital Medical Center (CCHMC) generously
gifted TTF-1 null mice. Animal husbandry and use fol-
lowed protocols approved by the Institutional Animal
Care and Use Committee at CCHMC and Brigham
Young University.
Antibodies
A rabbit a5 polyclonal antibody (generated and kindly
gifted by Scott Rogers and Lorise Gahring at the Univer-
sity of Utah) was generated against epitopes in the cyto-
plasmic domain of the a5 protein and has been
demonstrated to interact with tissues embedded in par-
affin [17,18]. Antibody specificity was confirmed using
immunoblotting and ELISA, revealing that the anti-
serum reacts only with the a5 subunit protein to which
it was made [19]. While data revealing positive immu-
nostaining for a subset of nAChR subunits in brain sam-
ples from both wild type and subunit null animals exists
[20,21], there are no published reports demonstrating
such effects in lung tissue or employing a5 specific anti-
bodies. The a5 IgG was used at a dilution of 1:800.
A rabbit polyclonal antibody raised against Clara Cell
Secretory Protein (CCSP) generated at the CCHMC was
used at a dilution of 1:1600 to identify Clara cells in the
conducting airways. A rabbit polyclonal antibody for
TTF-1 was also generated at CCHMC and used to loca-
lize type II alveolar epithelial cells (ATII) at a dilution of
1:1000. Specificity of the CCSP and TTF-1 antibodies
was determined by Western blot analysis (not shown).
Immunohistochemistry
Immunohistochemical staining for a5, CCSP, and TTF-1
were performed using standard techniques [22,23].
Briefly, 5-μm paraffin sections from six mice per group
were deparaffinized and rehydrated. Sections were trea-
ted with 3% hydrogen peroxide in methanol for 15 min
to quench endogenous peroxidase. Development in
NiDAB was followed by incubation in Tris-cobalt, which
enhanced antigen localization, and by counterstaining
with nuclear fast red. Sections were then dehydrated in
a series of ethanols, washed in three changes of xylene,
and mounted under coverslips with Permount. Control
sections were incubated in blocking serum alone.
Plasmid Construction and Mutagenesis
Primers were designed to retrieve 2.0-kb or 0.85-kp of
the mouse a5 promoter by polymerase chain reaction
(PCR) using the Expand High Fidelity PCR System
(Roche, Indianapolis, IN). The amplified a5 promoter
fragment was directionally cloned into the pGL4.10-
b a s i cl u c i f e r a s er e p o r t e rp lasmid (Promega, Madison,
WI) and verified by sequencing. Site-directed mutagen-
esis of potential TTF-1 binding sites was performed by
using the reporter construct (pGL4.10-0.85-kb a5)
and the QuickChange™ Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA). Briefly, synthetic oligonucleo-
tides containing the desired mutation for TTF-1
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tion. The products were digested with DpnIt or e m o v e
the wild-type DNA. The nicked vector DNA was then
transformed into XL1-blue supercompetent cells and
repaired. All constructs were verified by nucleotide
sequencing.
Transfection and Reporter Gene Assays
Functional assays of reporter gene constructs were per-
formed by transient transfection of Beas2B and A-549
cells using FuGENE-6 reagent (Roche). Beas2B is a
transformed human bronchiolar epithelial cell line and
A-549 is a human pulmonary adenocarcinoma cell line
characteristic of ATII cells. Cells in 35-mm dishes at
40-50% confluence were transfected with four plasmids
at the following concentrations: 300 ng pRSV-bgal, 100
ng pGL4.10-2.0-kb a5 or pGL4.10-0.85-kb a5, 100-400
ng pCMV-TTF-1 and pCDNA control vector to bring
total DNA concentration to 1.2 μg. The cells were
allowed to grow to confluence (48 hr), washed with cold
PBS, lysed, and snap frozen for several hours. The plates
were scraped and centrifuged, and the cleared superna-
tant was used for both b-gal and luciferase assays.
Reporter assays were normalized for transfection effi-
ciency based on the b-gal activity [22]. Luciferase activ-
ity was determined in 10 μl of extract at room
temperature with 100 μl of luciferase substrates A and B
(BD Biosciences, San Jose, CA) for 10 sec after a
2-sec delay in a Moonlight™ 3010 luminometer (BD
Biosciences).
RT-PCR
In order to assess a5 mRNA expression throughout
development, total RNA was isolated from whole mouse
lungs at various time points with the Absolutely RNA®
RT-PCR Miniprep Kit (Stratagene) and DNase treated.
Because a5 was immunolocalized in bronchioles and
alveoli, induction of a5 mRNA expression was similarly
assessed in Beas2B and A-549 cells following transfec-
tion with 400 ng pCMV-TTF-1 or control pCDNA vec-
tor. 2-μg of total RNA was reverse transcribed using the
SuperScript® III First-Strand Kit according to the manu-
facturer’s instructions (Invitrogen). PCR was performed
with 2-μla l i q u o t so ft h eg e n e r a t e dc D N Au s i n gT a q
polymerase (Roche, Indianapolis, IN) and experiments
included no template (lacking cDNA) and no RT (with-
out reverse transcriptase) controls (not shown). Products
were electrophoresed on a 1.5% agarose gel with appro-
priate molecular weight standards. Bands were quanti-
fied using Un-Scan-it™ gel digitizing software (Silk
Scientific, Orem, UT). Gene expression was assessed in
three replicate pools and representative data is shown.
Primers used for the PCR reactions include a5 forward
(5’-CTT CAC ACG CTT CCC AAA CT-3’) and reverse
(5’-CTT CAA CAA CCT CAC GGA CA-3’)a n d
GAPDH forward (5’-CGT CTT CAC CAC CAT GGA
GA-3’) and reverse (5’-CGG CCA TCA CGC CAC AGC
TT-3’). PCR parameters included an initial heating at
94°C for 5 m. a5 and GAPDH were amplified via
30 cycles at 94°C for 45 s, 57°C for 45 s, and 72°C for
45 s. All amplifications were followed by a 7-min exten-
sion at 72°C.
Statistical Analysis
Results are presented as the means ± S.D. of six repli-
cate pools per group. Means were assessed by one and
two-way analysis of variance (ANOVA). When ANOVA
indicated significant differences, student t tests were
used with Bonferroni correction for multiple compari-
sons. Results are representative and those with p values
< 0.05 were considered significant.
Results
a5 nAChR Expression During Lung Development
The distribution of a5 was assessed in mouse lung by
immunohistochemistry from E13.5 to PN20. At E13.5
(Figure 1A) and E15.5 (Figure 1B), a5 was predomi-
nantly observed in primitive airway epithelial cells and
sporadically detected in pulmonary mesenchyme. While
mesenchymal staining diminished through E18.5, a5
expression in pulmonary epithelium increased and was
restricted to luminal cell surfaces (Figure 1D). a5
expression was abundantly detected in proximal lung
epithelial cells at PN1 (Figure 1E), however, by PN4, a5
expression was only detected in the peripheral respira-
tory region of the lung (Figure 1F). Staining at PN4, a
period that coincides with the onset of alveologenesis,
revealed a5 expression in cells located near alveolar
septa characteristic of ATII localization. This pattern of
expression in respiratory epithelial cells and minimal to
no staining in the proximal lung persisted through
PN10 (Figure 1G). BY PN20, a5 expression was detected
throughout the lung, with abundant immunolocalization
in proximal airway epitheliuma sw e l la si nt h er e s p i r a -
tory compartment (Figure 1H). No staining was
observed in sections stained without primary antibody
(Figure 1I). The patterns of a5 expression obtained by
immunostaining corresponded with a5 mRNA expres-
sion from E13.5 to PN20 as revealed by semi-quantita-
tive RT-PCR analysis (Figure 2).
To identify epithelial cells that express a5, immuno-
histochemistry was performed on serial sections at PN1.
Staining serial sections with TTF-1 (Figure 3A), an ATII
cell marker, and a5 (Figure 3B), revealed a5 expression
in ATII cells with nuclear staining for TTF-1. While a5
was expressed in many ATII cells (Figure 3A and 3B,
arrows) not all ATII cells were identified with a5 stain-
ing. Localization in serial sections was also performed
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non-ciliated Clara cells in the proximal lung that slightly
protrude into the airway lumen (Figure 3C). a5 staining
(Figure 3D) appeared to be associated with many CCSP-
secreting Clara cells in pulmonary bronchioles (Figure 3C).
TTF-1 Regulates a5 Transcription In Vitro
Because there were interesting shifts in the expression of
a5 by ATII cells at various developmental time points
(Figure 1E,F,G,H), experiments were planned that tested
whether TTF-1 transcriptionally regulates a5 expression.
An assessment of the mouse a5 promoter sequence
revealed the locations of nine potential TTF-1 regulatory
elements (TREs) in the 2.0-kb promoter fragment and
five in the 0.85-kb fragment (Figure 4A). Because a5
experienced profound expression changes from proximal
lung (Figure 1E) to distal lung (Figure 1F and 1G) before
returning to the proximal lung (Figure 1H), we tested
the degree of TTF-1 regulation in both bronchiolar
epithelium (Beas2B) and ATII-like alveolar epithelial
cells (A-549). TTF-1 (100-400 ng) activated the 2.0-kb
a5 promoter in a dose-dependent manner in both
Beas2B and A549 cells (Figure 4B and 4C). TTF-1 also
significantly induced transcription of a5 in both cell
types when a truncated reporter that contains only
Figure 1 Immunostaining revealed distinct patterns of a5 expression in the lung during organogenesis.A .a5 was expressed at E13.5 in
primitive airway epithelium (arrow) and sporadically in pulmonary mesenchyme (arrowhead). B and C. During the late pseudoglandular period
of development (B, E15.5) and early saccular stage of development (C, E17.5), a5 continued to localize to pulmonary epithelium (arrows). D. At
E18.5, a5 expression was detected in larger airways (arrows) as well as in primitive respiratory epithelium (arrowhead). E. At PN1, a5 expression
was markedly detected in proximal lung airways (arrow) and only minimally detected in the peripheral lung (arrowhead). F. At the
commencement of alveologenesis (PN4), a5 localized to lung parenchyma (arrow) and was noticeably absent in the airways (arrowhead). G. At
PN10, a5 expression persisted in the respiratory compartment (arrow). H. After alveologenesis progressed to PN20, a5 was abundantly expressed
throughout the lung, being detected in proximal (arrow) as well as distal pulmonary epithelium (arrowhead). I. PN20 sections incubated without
primary a5 antibody revealed no immunoreactivity. Six mice were included in each group and representative images at 40× magnification are
shown.
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Page 4 of 100.85-kb of the promoter was transfected (Figure 4D and
4E).
To identify potential TREs that are critical in TTF-1-
mediated control of a5 transcription, site-directed muta-
tional analysis was performed resulting in the ablation
of putative TREs (Figure 5A). In Beas2B cells, mutation
of the second and fourth TRE resulted in a significant
decrease in TTF-1-induced transcription compared to
the wild type promoter transfected with TTF-1 (Figure
5B). Experiments involving A-549 cells revealed that
mutation of any of the five TREs resulted in a significant
decrease in TTF-1-induced transcription (Figure 5B).
TTF-1 Mediates a5 Expression In Vitro
In order to further assess the effects of TTF-1 on a5
expression, Beas2B and A-549 cells were transfected
with TTF-1 and a5 was assessed by RT-PCR. In the
absence of exogenous TTF-1, Beas2B and A-549 cells
both expressed detectible levels of a5 (Figure 6). Trans-
fection of TTF-1 24 hours before RNA isolation induced
a significant increase in a5 mRNA expression in both
A-549 and Beas2B cells (Figure 6).
TTF-1 Targeting Impairs a5 Expression In Vivo
Because our data demonstrate that a5 is expressed in
pulmonary epithelium at E18.5 (Figure 1D) and its
expression is regulated by TTF-1 (Figures 4, 5, 6), we
determined a5 expression in TTF-1 null mice. TTF-1
null mice die at birth due to significantly reduced
branching morphogenesis and severe lung hypoplasia.
Expression of a5 in pulmonary epithelium in the lungs
of TTF-1 null mice (Figure 7A, arrow) was nearly unde-
tectable when compared to intense a5 localization
observed in age-matched wild type control lung samples
(Figure 7B, arrows).
Discussion and Conclusions
The temporal-spatial distribution of a5, a member of the
nicotinic acetylcholine receptor subunit family, was
determined during embryonic and postnatal lung devel-
opment. Various epithelial cell populations expressed a5
protein in both the conducting and peripheral air
spaces. a5 was primarily expressed in respiratory epithe-
lial cells during the embryonic, pseudoglandular, canna-
licular, and saccular stages of lung development. In
addition to expression in the peripheral lung, a5 was
also detected perinatally in distinct populations of
bronchiolar epithelial cells. Conducting airway epithelial
cell expression persisted throughout lung morphogenesis
except from PN4 to PN10, a period that coincides with
significant parenchymal differentiation in the alveolar
stage of lung development. Immunolabeling of a5 in the
fetal lung was observed primarily on luminal epithelial
cell membranes suggesting that a5 accumulates on api-
cal cell surfaces in order assemble receptors needed in
the postnatal lung. Alternatively, apical expression may
suggest that a5 subunits combine in utero to form func-
tional nAChRs which bind ligand and signal events that
are essential during organogenesis. Several groups have
shown that nAChRs are expressed in airway epithelium
and that they form functional receptors as demonstrated
by electrophysiological analyses [8,24,25]. Localization of
a5 with cells that express CCSP and TTF-1 suggests
that a5 is regulated by TTF-1 and, therefore, may
play a role in the mediation of paracrine signaling
between respiratory epithelial cells during pulmonary
morphogenesis.
Intriguing aspects of functional pulmonary nAChRs
in utero are data related to acetylcholine (ACh) as a
local signaling molecule synthesized by many non-
neuronal cells [26]. In order for ACh to function as a
signal in the lung, ACh must be synthesized and
secreted locally. Choline is incorporated into pulmonary
bronchiolar cells by a choline high-affinity transporter
(CHT), synthesized into ACh by choline acetyl transfer-
ase (ChAT), and packaged into transport vesicles by a
vesicular ACh transporter (VAChT) [26]. Availability of
choline in the lung is also possible due to its derivation
during the recycling of surfactant proteins and mem-
branes [27]. In addition to acetylation during the gen-
eration of ACh, choline has also been demonstrated to
be an agonist for a subset of ligand binding nAChR sub-
units such as a7 [28]. While evidence for choline and
acetylcholine ligation primarily identifies with the
Figure 2 a5 mRNA expression in the lung during
organogenesis. Semi-quantitative RT-PCR analysis revealed variable
abundance of a5 mRNA expression in whole mouse lung from
E13.5 to PN20. Band densities were assessed and normalized after
standardization of GAPDH band densities to 1. Although samples
were screened from 6 mice at each time point, only a
representative single band is shown.
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Page 5 of 10Figure 3 a5 was expressed by and ATII cells Clara cells at PN1. Staining for TTF-1 (A) and a5 (B) in serial sections from PN1 mouse lung
revealed a5 is co-expressed with TTF-1 in many ATII cells, but not all (arrows). Staining for CCSP (C) and a5 (D) also identified consistent a5
expression in bronchiolar epithelium at PN1 (arrows). All images are at 80× original magnification.
Figure 4 TTF-1 activated a5 transcription in bronchiolar and alveolar epithelial cell types.A .S c h e m a t i co fa5 luciferase reporters
containing 2.0-kb or 0.85-kb mouse a5 promoter sequences that include putative TTF-1 response elements (TREs, black rectangles). B and C. TTF-
1 dose-dependently induced a5 transcription by acting on a 2.0-kb a5 reporter in Beas2B (B) and A-549 (C) cells. D and E. TTF-1 also induced
significant increases in a5 transcription via interaction with a truncated 0.85-kb a5 reporter. Significant differences in luciferase levels compared
to reporter alone are noted at P ≤ 0.05 (*).
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interact with receptors structurally maintained by a5.
a5 was co-expressed with TTF-1 in epithelial cells that
contribute to primordial tubules early in lung develop-
ment [29]. TTF-1 regulates cytodifferentiation and for-
mation of functional respiratory epithelium [5]. Several
additional co-expressed transcriptional regulators such
as GATA-6 and FoxA2 are also observed in airway
epithelium during the period from E13.5 to 15.5 [3,30].
Recent preliminary studies performed in our laboratory
reveal that GATA-6 and FoxA2, both transcriptional
targets of TTF-1, also individually and synergistically
activate the a5 promoter, suggesting complex interplay
between TTF-1 and other important transcription fac-
tors. TTF-1 and various co-regulators such as GATA-6
and FoxA2 interact during the regulation of specific
genes critical to lung function, including CCSP, surfac-
tant proteins, growth factors, and VEGFa and VEGFr2
essential in vasculogenesis [31]. While additional
research is still necessary, the observations that a5 was
transcriptionally induced by TTF-1 via interaction with
specific promoter response elements and significantly
diminished in TTF-1 null mouse lung reveals the impor-
tance of TTF-1 in the orchestration of a5 regulation.
This research also demonstrates that a5 and other
nAChR subunits such as a7 [16] may contribute to an
expanding group of important developmental genes
regulated by TTF-1. Furthermore, because the a5 gene
and message maintain remarkable conservation across
species (Table 1), TTF-1 and its homologues may
Figure 5 TTF-1 induced a5 transcription via interaction with putative TTF-1 response elements (TREs). A. Schematic of a wild type (WT)
a5 luciferase reporter containing the 0.85-kb mouse a5 promoter sequence and reporters that contain a 0.85-kb a5 promoter with each
sequential TRE targeted by site-directed mutagenesis (Mutants A-E). B. TTF-1-mediated increases in a5 transcription were significantly diminished
in Beas2B cells when the second or fourth TREs were mutated. C. Each TRE was demonstrated to be significant in regulating TTF-1-mediated a5
transcription in ATII-like A-549 cells. Significant decreases in TTF-1 induced luciferase activity resulting from each mutant reporter compared to
WT + TTF-1 are noted at P ≤ 0.05 (*).
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Page 7 of 10Figure 6 a5 mRNA expression was induced by TTF-1 in ATII-like A-549 cells and bronchiolar epithelium-like Beas2B cells.A .B ys e m i -
quantitative RT-PCR analysis, A-549 and Beas2B cells endogenously express a5. Transfection with a TTF-1 expression vector 24 hours prior to
mRNA isolation, reverse transcription, and PCR amplification resulted in detectible increases in a5 expression. Representative examples are shown.
B. Band densities from six replicates per group were assessed and normalized after standardizing GAPDH band density to 1. When all six
replicates were assessed, a significant difference in a5 expression was detected between TTF-1 and mock transfected cells (*P ≤ 0.05).
Figure 7 a5 expression was significantly reduced in pulmonary epithelium from E18.5 TTF-1 null mice compared to age-matched with
type controls.A .a5 immunostaining in TTF-null mouse lung revealed almost complete ablation of a5 expression in pulmonary epithelium
(arrow). B. Staining for a5 demonstrated marked expression in proximal and distal pulmonary epithelium (arrows). All images are at 40× original
magnification.
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in the defined temporal and spatial pattern of a5
nAChR expression in the lung.
Even though TTF-1 specifically induced significant a5
expression in pulmonary epithelium, the temporal-
spatial distribution of TTF-1 and a5 during lung develop-
ment were not completely identical. For example, whereas
TTF-1 is an epithelium-specific transcription factor, a5
protein was expressed in both the epithelium and
mesenchyme at E13.5. The expression of a5 is therefore
likely regulated by the activity of several transcription fac-
tors with overlapping expression patterns. Because TTF-1
regulates target gene expression in concert with other reg-
ulatory factors including GATA-6, FoxA2, NF-1, RAR,
and AP-1 [31], it is likely that the temporal-spatial distri-
bution of a5 expression is influenced in a complex manner
by a host of transcription factors.
Nicotinic cholinergic signaling via a5 nAChR subunits
in airway epithelial cells is likely affected by nicotine.
Published reports demonstrate that cells exposed to
environmental tobacco smoke, or equal concentrations
of nicotine, induce sequential severalfold increases in a5
and a7 expression [32]. Plasma nicotine levels in smo-
kers fluctuate between 10 and 200 nM and epithelial
cells directly exposed to smoke may experience nicotine
levels that are 5-10-fold greater [33,34]. Exposure to
cigarette smoke during pregnancy adversely affects lung
development as manifested by significantly reduced
branching morphogenesis [35], increased respiratory ill-
ness [36], altered pulmonary function [37], and perma-
nent airway obstruction in the proximal lung [38].
Nicotine crosses the placenta and directly affects lung
development in utero via interaction with nAChRs in
the developing and post-natal lung. Our studies demon-
strate that while receptors that contain a5 are expressed
in populations of epithelial cells during lung develop-
ment, receptor availability may contribute to adverse
lung development and morphological perturbation when
noxious ligands are present.
Recently the a5 gene (CHRNA5) and other receptor
subunits located in the chromosome 15q24-25 region
have been the topics of intense investigation due to a
correlation between an a5 variant and nicotine depen-
dence [39]. While research is ongoing, analysis of this
specific chromosomal locus reveals that a5 and its var-
iants significantly influence susceptibility to smoke
related lung cancer and chronic obstructive pulmonary
disease (COPD) [39-41]. Understanding the develop-
mental role of a5 and TTF-1-mediated mechanisms that
control its precise pattern of expression during lung
organogenesis will prove beneficial in elucidating the
role of a5 in the progression of lung disease commenced
in utero by tobacco exposure.
In conclusion, a5 nAChR subunits are expressed in
specific epithelial cell types in the lung during develop-
ment. a5 expression is developmentally regulated by sev-
eral factors including TTF-1, a molecule centrally
involved in normal lung formation. Our data reveals
specific regulation of a5 expression by TTF-1; however,
such expression may be altered by nicotine exposure.
While nicotine may directly influence normal choliner-
gic signaling during morphogenesis that involves a5-
containing nAChRs, the misregulation of a5 may also
predispose individuals to lung cancer and COPD.
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